Petros Pharmaceuticals, Inc.
PTPI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815903
No open-market purchases or sales by Petros Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Petros Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −2 vs. Q4 2021
- Shares held
- 834.5K
- −241.1K (−22.4%) vs. Q4 2021
- Total value
- $1.30M
- −$2.28M (−63.6%) vs. Q4 2021
- New holders
- 4
- 7 more added
- Sold out
- 6
- 2 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTPI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 15 | $77.6K |
| Q4 2024 | 9 | $38.5K |
| Q3 2024 | 11 | $59.2K |
| Q2 2024 | 12 | $94.9K |
| Q1 2024 | 13 | $94.9K |
| Q4 2023 | 16 | $164.7K |
| Q3 2023 | 14 | $170.6K |
| Q2 2023 | 14 | $214.3K |
| Q1 2023 | 9 | $42.7K |
| Q4 2022 | 10 | $90.6K |
| Q3 2022 | 13 | $355.0K |
| Q2 2022 | 16 | $558.0K |
| Q1 2022 | 19 | $1.30M |
| Q4 2021 | 21 | $3.58M |
| Q3 2021 | 19 | $1.82M |
| Q2 2021 | 22 | $3.02M |
| Q1 2021 | 20 | $4.23M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Petros Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 83 | $0 | 0.00% | +23+38.3% | Added |
| First Manhattan Co | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 57 | $0 | 0.00% | 00.0% | Unchanged |
| Cutler Group LP | 400 | $0 | 0.00% | +400 | New |
| Newbridge Financial Services Group, Inc. | 1,200 | $2.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 1,135 | $2.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 3,869 | $6.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,924 | $6.00K | 0.00% | +708+22.0% | Added |
| UBS Group AG | 4,820 | $8.00K | 0.00% | +2,771+135.2% | Added |
| Simplex Trading, LLC | 9,883 | $15.0K | 0.00% | +9,883 | New |
| Emfo, LLC | 10,000 | $16.0K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 45,439 | $71.0K | 0.00% | +839+1.9% | Added |
| Citadel Advisors LLC | 68,970 | $107.0K | 0.00% | +68,970 | New |
| Geode Capital Management, LLC | 69,920 | $109.0K | 0.00% | +11,135+18.9% | Added |
| Two Sigma Advisers, LP | 73,800 | $115.0K | 0.00% | +61,800+515.0% | Added |
| Two Sigma Investments, LP | 104,120 | $162.0K | 0.00% | +104,120 | New |
| Vanguard Group Inc | 113,823 | $178.0K | 0.00% | −37,424−24.7% | Reduced |
| Marshall Wace, LLP | 131,196 | $205.0K | 0.00% | −112,884−46.2% | Reduced |
| BlackRock Inc. | 191,715 | $300.0K | 0.00% | +172,156+880.2% | Added |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −342,900−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −67,640−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −53,019−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −35,814−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −13,705−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −10,494−100.0% | Sold out |